I'm LongbridgeAI, I can summarize articles.Jefferies analyst Akash Tewari reaffirmed a Buy rating on Damora Therapeutics (DMRA) with a $50 price target, citing the differentiated profile of its lead candidate DMR-001 for essential thrombocythemia and myelofibrosis. Key advantages include enhanced potency against Type 2 CALR mutations and convenient dosing. H.C. Wainwright also reiterated a Buy rating with a $45 price target.
Damora Therapeutics (DMRA) has received a new Buy rating, initiated by Jefferies analyst, Akash Tewari.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Akash Tewari has given his Buy rating due to a combination of factors, starting with the differentiated profile of Damora’s lead candidate DMR-001 in essential thrombocythemia and myelofibrosis. He views the drug’s enhanced potency against Type 2 CALR mutations, stronger binding characteristics, and extended half‑life as key advantages that can translate into superior clinical outcomes versus INCY’s INCA‑989.
He also emphasizes the potential for more convenient, infrequent subcutaneous dosing and a more compelling first‑line strategy in myelofibrosis, which could improve patient adoption and market penetration. Combined with additional upside from the broader pipeline and his risk‑adjusted peak sales estimate of roughly $2.2 billion in ET/MF, Tewari concludes that Damora’s current valuation still leaves room for meaningful appreciation, supporting his Buy rating and $50 price target.
Tewari covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Pfizer, and Ionis Pharmaceuticals. According to TipRanks, Tewari has an average return of 13.6% and a 56.64% success rate on recommended stocks.
In another report released on July 21, H.C. Wainwright also reiterated a Buy rating on the stock with a $45.00 price target.